Praising the German government for its aggressive approach to unearth black money stashed offshore, WikiLeaks founder Julian Assange said that India "should be more aggressive because India seems like it is loosing per capita much more tax than Germany"
New Delhi: In comments that could fuel a fresh controversy over the black money issue, WikiLeaks founder Julian Assange Tuesday said there are Indian names in the Swiss bank data list that are going to be made public, reports PTI.
"Yes, there are Indian names in the data that we have already published or are going to publish. I can't remember specifically whether there are Indian names in the coming publication. But I have read Indian names," Mr Assange told Times Now.
Indicating that there are bigwigs among the Indians having their accounts in Swiss banks, he said, "Similarly, in these private Swiss banking concerns, where you need at least a million dollars, which is a significant amount of money...not an average Indian..."
Asked whether the names will come at any point, he said on "that, you should absolutely not loose hope".
He, however, declined to reveal anything more on the issue at this stage.
Noting that he has come to know through a report that there are more Indian deposits in the Swiss banks than any other nationality, Mr Assange said, "There is no reason why India should not be aggressive."
Praising the German government for its aggressive approach to unearth black money stashed offshore, he said that India "should be more aggressive because India seems like it is loosing per capita much more tax than Germany."
Mr Assange alleged that Indian government's response to the WikiLeaks cables was "one of the worst in the world" and a "clear attempt to mislead the nation on what the cables were".
He said that the response by the Indian government left a lot to be desired.
Mr Assange also dismissed contention of the Indian government that accords on double taxation were coming in the way of tracking the trail of black money.
"Double taxation does not have anything to do with asset hiding. It doesn't simply cover asset hiding," he said.
Mr Assange said that issue of stashing black money in foreign banks was much worse than just local corruption as when money is pushed offshore, ".....then every time they are selling rupees and the result is that the currency of the nation is debased...everything for all Indians become more expensive as a result of that transfer."
Mr Assange had earlier claimed that he was handed over documents of bank accounts by a former banker Rudolf Elmer and the whistleblower also claimed that the names in the documents came from "US, Britain, Germany, Austria and Asia-from all over," and include "business people, politicians, people who have made their living in the arts and multinational conglomerates-from both sides of the Atlantic".
Pharma major, Lupin and its subsidiaries, Lupin Pharmaceuticals, Inc and Lupin Atlantis Holding S.A., have entered a license agreement with Abbott Laboratories and Laboratoires Fournier S.A
Pharma major, Lupin and its subsidiaries, Lupin Pharmaceuticals, Inc and Lupin Atlantis Holding S.A., have entered a license agreement with Abbott Laboratories and Laboratoires Fournier S.A. for various Abbott patents for Antara (Fenofibrate) Capsules.
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.
On Tuesday, Lupin ended 1.09% up at Rs419.20 on the Bombay Stock Exchange, while the benchmark Sensex ended 0.20% to 19,545.35.
Tumatrek, a unique and cost effective diagnostic tool for cancer can also detect malignancy even through a simple X-ray
Venus Remedies, a research based pharma MNC has successfully completed Phase I & II clinical trial for VRP1620, a cancer detection molecule. The clinical study has shown excellent results in detection of breast cancer. With this drug detection of breast cancer would be possible even with a simple X-ray using dye and the sensitivity of other detection devices such as coloured doppler, PET would be increased several times.
Dr Manu Chaudhary, Research Director of the company said, "VRP 1620 (Tumatrek) is a unique and cost effective diagnostic tool for cancer which can also detect malignancy even through X-ray. It can detect cancer at lesser cost and at primary stage itself." By detection of cancer at early stage it can increase the cure rate. Scientists believe that after Phase III trials of this product VRP-1620 may also help in locating proliferation of cancer site. There are lots of opportunities where the usage of this product can be extrapolated for the benefit of humanity.
A team of scientists from Venus Medicines Research Center (VMRC), R&D wing of the company were working for past couple of years on a novel peptide VRP 1620, which is highly selective ETB receptor agonist and is involved in selective vasodilation in solid tumors. "Phase III will be completed this year only and product will be ready for market launch in early 2012." Dr. Chaudhary added.
Venus Remedies has completed and submitted the report of Phase I & II study on breast cancer patients for VRP 1620 after due permission from IND Committee and DCGI, Govt. of India. This clinical study documented the pharmacokinetic profile and appropriate dose range for the drug. It also described the efficacy for its use as a diagnostic agent for breast cancer. The efficacy was gauged by observing increase in diameter and the corresponding change in resistive index of tumor vessel.
On Tuesday, Venus Remedies ended 1.08% up at Rs220.25 on the Bombay Stock Exchange, while the benchmark Sensex ended 0.20% to 19,545.35.